tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Abnormalities, Multiple D000015 13 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Acne Vulgaris D000152 35 associated lipids
Adenocarcinoma D000230 166 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Akinetic Mutism D000405 1 associated lipids
Albuminuria D000419 18 associated lipids
Alopecia D000505 14 associated lipids
Alopecia Areata D000506 6 associated lipids
Alzheimer Disease D000544 76 associated lipids
Amenorrhea D000568 4 associated lipids
Amputation, Traumatic D000673 2 associated lipids
Anemia D000740 21 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Anemia, Hemolytic, Autoimmune D000744 5 associated lipids
Anemia, Refractory D000753 3 associated lipids
Anemia, Refractory, with Excess of Blasts D000754 2 associated lipids
Aneurysm, Dissecting D000784 2 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Porayko MK et al. Nephrotoxicity of FK 506 and cyclosporine when used as primary immunosuppression in liver transplant recipients. 1993 Transplant. Proc. pmid:7679835
Shapiro R et al. Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation: preliminary report. 1993 Transplant. Proc. pmid:7679836
Propper DJ et al. Effects of the immunosuppressive macrolides rapamycin and FK 506 in high responder rats presensitized to major histocompatibility complex antigens. 1993 Transplant. Proc. pmid:7679837
Stock PG et al. Standard sequential immunosuppression with Minnesota antilymphoblast globulin and cyclosporine vs FK 506: a comparison of early nephrotoxicity. 1993 Transplant. Proc. pmid:7679838
Tabasco-Minguillan J et al. Long-term insulin requirement after liver transplantation with FK 506 in American veterans. 1993 Transplant. Proc. pmid:7679839
Klintmalm GB et al. Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group. 1993 Transplant. Proc. pmid:7679840
Jayaraman T and Marks AR Rapamycin-FKBP12 blocks proliferation, induces differentiation, and inhibits cdc2 kinase activity in a myogenic cell line. 1993 J. Biol. Chem. pmid:7503980
Saeki T et al. Human P-glycoprotein transports cyclosporin A and FK506. 1993 J. Biol. Chem. pmid:7681059
D'Ambrosio R et al. Validation and quality assurance program for monitoring tacrolimus (FK 506) concentrations in plasma and whole blood. 1993 Ther Drug Monit pmid:7504339
Dutz JP et al. A role for calcineurin in degranulation of murine cytotoxic T lymphocytes. 1993 J. Immunol. pmid:7681074
Takeguchi N et al. Inhibition of the multidrug efflux pump in isolated hepatocyte couplets by immunosuppressants FK506 and cyclosporine. 1993 Transplantation pmid:7681229
Valdivia LA et al. Successful hamster-to-rat liver xenotransplantation under FK506 immunosuppression induces unresponsiveness to hamster heart and skin. 1993 Transplantation pmid:7681230
Fujimura A et al. Chronopharmacokinetic study of a new immunosuppressive agent, FK 506, in mice. 1993 Jpn. J. Pharmacol. pmid:7681489
Winkler ME et al. Successful pregnancy in a patient after liver transplantation maintained on FK 506. 1993 Transplantation pmid:7506460
Yoshizawa K et al. Establishment of Epstein-Barr virus-associated lymphoma cell line SUBL with t(2;3)(p11;q27) from a liver transplant patient. 1993 Cancer Genet. Cytogenet. pmid:7506636
Peters DH et al. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. 1993 Drugs pmid:7506654
Mühl H et al. Cyclosporin derivatives inhibit interleukin 1 beta induction of nitric oxide synthase in renal mesangial cells. 1993 Eur. J. Pharmacol. pmid:7506668
Schulz BS et al. Increased expression of epidermal IL-8 receptor in psoriasis. Down-regulation by FK-506 in vitro. 1993 J. Immunol. pmid:7691948
Nagata K et al. Failure of FK-506, a new immunosuppressant, to prevent cerebral vasospasm in a canine two-hemorrhage model. 1993 J. Neurosurg. pmid:7692019
Lhoëst G et al. Isolation and identification by FAB mass spectrometry and NMR spectroscopy of a demethylated metabolite of FK506 from erythromycin-induced rabbit liver microsomes. 1993 Pharm Acta Helv pmid:7692454
Izumi S and Okuhara M [FK506 and kifunensine, new immunomodulators of microbial origin]. 1993 Tanpakushitsu Kakusan Koso pmid:7692469
Wakugami T et al. Effect of FK506 on the development of diabetes in BB rats in comparison with that of cyclosporin. 1993 Tohoku J. Exp. Med. pmid:7692621
Kunz J and Hall MN Cyclosporin A, FK506 and rapamycin: more than just immunosuppression. 1993 Trends Biochem. Sci. pmid:7694398
Bierer BE et al. Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology. 1993 Curr. Opin. Immunol. pmid:7694595
White DJ Immunosuppression for heart transplantation. 1993 Br. J. Biomed. Sci. pmid:7694717
Blaehr H et al. Acute effects of FK506 and cyclosporine A on cultured human proximal tubular cells. 1993 Eur. J. Pharmacol. pmid:7683267
Kadmon M et al. Inhibition by cyclosporin A of adenosine triphosphate-dependent transport from the hepatocyte into bile. 1993 Gastroenterology pmid:7683296
Denesyuk AI et al. Structural similarity of the binding sites of cyclophilin A-cyclosporin A and FKBP-FK506 systems. 1993 Biochem. Biophys. Res. Commun. pmid:7683466
Suzuki S et al. Neutrophil infiltration as an important factor in liver ischemia and reperfusion injury. Modulating effects of FK506 and cyclosporine. 1993 Transplantation pmid:7685932
McDiarmid SV et al. Differences in oral FK506 dose requirements between adult and pediatric liver transplant patients. 1993 Transplantation pmid:7685933
Moutabarrik A et al. Use of FK 506 in kidney transplantation. 1993 Transplant. Proc. pmid:7685946
Moutabarrik A et al. Effect of FK 506 and cyclosporine on the expression of IL-6 and its receptor on stimulated monocytes. 1993 Transplant. Proc. pmid:7685949
Takaya S et al. Use of prostaglandin E1 in crossmatch-negative liver transplant recipients treated with FK 506. 1993 Transplant. Proc. pmid:7685953
Machida M [Effect of temperature on plasma concentration of FK506]. 1993 Nippon Hinyokika Gakkai Zasshi pmid:7688443
Schmid FX Prolyl isomerase: enzymatic catalysis of slow protein-folding reactions. 1993 Annu Rev Biophys Biomol Struct pmid:7688608
Lyson T et al. Cyclosporine- and FK506-induced sympathetic activation correlates with calcineurin-mediated inhibition of T-cell signaling. 1993 Circ. Res. pmid:7688670
Morkawa K et al. Immunosuppressive property of bromocriptine on human B lymphocyte function in vitro. 1993 Clin. Exp. Immunol. pmid:7688676
Yamaoka K et al. Cyclosporin A and FK506 block the negative signaling mediated by surface IgM cross-linking in normal human mature B cells. 1993 Immunol. Lett. pmid:7688712
Smith DF et al. Two FKBP-related proteins are associated with progesterone receptor complexes. 1993 J. Biol. Chem. pmid:7688746
Clardy J Structural studies of complexed FK-506 binding protein. 1993 Ann. N. Y. Acad. Sci. pmid:7689808
Starzl TE et al. Allograft and xenograft acceptance under FK-506 and other immunosuppressant treatment. 1993 Ann. N. Y. Acad. Sci. pmid:7689809
Reem GH et al. FK-506 inhibits the IL-2-independent induction of the activation antigen CD 69. 1993 Ann. N. Y. Acad. Sci. pmid:7689811
Mollison KW et al. Comparison of FK-506, rapamycin, ascomycin, and cyclosporine in mouse models of host-versus-graft disease and heterotopic heart transplantation. 1993 Ann. N. Y. Acad. Sci. pmid:7689812
Tai PK et al. P59 (FK506 binding protein 59) interaction with heat shock proteins is highly conserved and may involve proteins other than steroid receptors. 1993 Biochemistry pmid:7689858
Barthelmess IB and Tropschug M FK506-binding protein of Neurospora crassa (NcFKBP) mediates sensitivity to the immunosuppressant FK506; resistant mutants identify two loci. 1993 Curr. Genet. pmid:7679056
Fingar DC et al. Dissociation of pp70 ribosomal protein S6 kinase from insulin-stimulated glucose transport in 3T3-L1 adipocytes. 1993 J. Biol. Chem. pmid:7679106
Griffiths EJ and Halestrap AP Protection by Cyclosporin A of ischemia/reperfusion-induced damage in isolated rat hearts. 1993 J. Mol. Cell. Cardiol. pmid:7512654
McCaffrey PG et al. NF-ATp, a T lymphocyte DNA-binding protein that is a target for calcineurin and immunosuppressive drugs. 1993 J. Biol. Chem. pmid:7679116
Armitage JM et al. Pediatric lung transplantation. The years 1985 to 1992 and the clinical trial of FK 506. 1993 J. Thorac. Cardiovasc. Surg. pmid:7679172
Ito K and Komatsu Y [Drug induced hemolytic uremic syndrome]. 1993 Nippon Rinsho pmid:7679450